Relationship of the level of soluble PD-L1 and its relevant proteins in peripheral blood with the prognosis of patients with NSCLC

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cancer Biology
Pathology/Molecular Biology
Translational Research
Presenter Ge Bai
Citation Annals of Oncology (2018) 29 (suppl_9): ix143-ix149. 10.1093/annonc/mdy446
Authors G. Bai1, Y. Xu2, M. Wang2
  • 1Pumc, PUMCH, 100730 - Beijing/CN
  • 2Respiratory Medicine, PUMCH, beijing/CN

Abstract

Background

This study aims to explore the value of soluble PD-L1 and its relevant proteins in peripheral blood in predicting the prognosis of patients with NSCLC.

Methods

Patients with advanced NSCLC who were admitted to Peking Union Medical College Hospital after Jan 2012 were included. Patients with EGFR or ALK mutation, autoimmune diseases or other malignancies were excluded. Enzyme-linked immunosorbent assay was utilized to determine the concentration of soluble PD-L1, CXCL9, SDR5, MMP-9, membrane PD-L1 and IFN-γ in peripheral blood samples obtained before chemotherapy. Prognostic data were gained by telephone interviews to calculate overall survival (OS) and progression-free survival (PFS) rate. Kaplan-Meier curves and multivariate COX regression were used to reveal the impact of these proteins on the prognosis.

Results

A total of 102 patients with a mean age of 61.5 years at the diagnosis were enrolled. 50 patients have adenocarcinoma and 52 patients have squamous cell carcinoma. The level of soluble PD-L1 and its relevant proteins were statistically comparable between subjects with various gender, age, pathological classification or LDH concentration. However, the level of soluble PD-L1 was significantly elevated in heavy-smokers and patients with late clinical stage. In multivariate analysis, higher level of soluble PD-L1 was associated with poorer PFS in adenocarcinoma group (HR = 0.44, 95%CI: 0.20-0.95) but better PFS in squamous cell carcinoma group (HR = 2.16, 95%CI: 1.05-4.43). Regarding OS, LDH is the only independent risk factor both in adenocarcinoma (HR = 0.03, 95%CI: 0-0.36) and squamous cell carcinoma group (HR = 0.08, 95%CI: 0.01-0.80).

Conclusions

NSCLC patients with late clinical stage and heavy smoking tend to have higher level of soluble PD-L1 in their peripheral blood. Higher level of soluble PD-L1 is related to poorer PFS in patients with adenocarcinoma but better PFS in patients with squamous cell carcinoma. LDH is a risk factor of poor OS in all NSCLC patients.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The Ethics Committee of Peking Union Medical College Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.